Alitretinoin in treatment of chronic hand eczema – mechanism of action

Maria Matejko; Beata Kręcisz

doi:10.5114/dr.2016.62893

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

5/2016
vol. 103

Send email

Copy url:

abstract:

Review paper

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Maria Matejko

,

Beata Kręcisz

Przegl Dermatol 2016, 103, 405–408

DOI: https://doi.org/10.5114/dr.2016.62893

Online publish date: 2016/10/20

View full text Get citation

PlumX metrics:

Hand eczema is a common skin disorder with significant functional and economic impacts. Conventional therapy options, such as topical corticosteroids, calcineurin inhibitors, phototherapy and systemic immunosuppressants, often give unsatisfactory results, due to lack of efficacy or predominant adverse effects. Alitretinoin (9-cis-retinoic acid) is an active substance from the group of retinoids and is licensed as a systemic drug for chronic and severe hand eczema refractory to topical treatment. It binds with high affinity to both retinoic acid receptor (RAR) and retinoid X receptor (RXR) receptors and presents anti-inflammatory and immunomodulatory activity. Due to its good tolerance and high efficacy, demonstrated in several large clinical studies, alitretinoin may be an option for patients with severe chronic hand eczema refractory to other treatment.

keywords:

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Maria Matejko , Beata Kręcisz

contact dermatitis, hand eczema refractory to treatment, 9-cis-retinoic acid, alitretinoin

Maria Matejko

,

Beata Kręcisz